Back

AMP to test FuseRx radiation oncology platform in Syracuse proof of concept

Verifying
  • AMP will run a FuseRx radiation oncology workflow proof of concept in Syracuse.
  • The American Cancer Society expects about 333,800 new U.S. prostate cancer cases in 2026.
  • AMP will begin with physician consultations before expanding FuseRx across treatment-team roles.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.
AMP to test FuseRx radiation oncology platform in Syracuse proof of concept - CoinPost Terminal